Vascular smooth muscle Jak2 deletion prevents angiotensin II-mediated neointima formation following injury in mice

被引:29
作者
Kirabo, Annet [1 ]
Oh, S. Paul [1 ]
Kasahara, Hideko [1 ]
Wagner, Kay-Uwe [2 ,3 ]
Sayeski, Peter P. [1 ]
机构
[1] Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA
[2] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[3] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA
基金
美国国家卫生研究院;
关键词
Jak2; Neointima; Angiotensin II; Vascular injury; Vascular smooth muscle cells; JAK/STAT SIGNALING PATHWAY; TRANSGENIC MICE; CELL DIFFERENTIATION; MOLECULAR REGULATION; GROWTH-FACTOR; RAT; PROLIFERATION; TRANSCRIPTION; KINASE; PHOSPHORYLATION;
D O I
10.1016/j.yjmcc.2011.03.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The in vitro treatment of vascular smooth muscle cells (VSMC) with angiotensin U (Ang II) causes Janus kinase 2 (Jak2) to interact with the Ang II type 1 receptor (AT(1)-R) resulting in enhanced cell growth. However, the role that Jak2 plays in AT(1)-R-mediated vascular cell growth and remodeling in vivo is less clear. We hypothesized that in vivo, Jak2 plays a rate-limiting role in Ang II-mediated neointima formation following vascular injury. Using the Cre-loxP system, we conditionally ablated Jak2 from the VSMC of mice. We found that these mice are protected from Ang II-mediated neointima formation following iron chloride-induced vascular injury. In addition, the VSMC Jak2 null mice were protected from injury-induced vascular fibrosis and the pathological loss of the contractile marker, smooth muscle a-actin. Finally, when compared to controls, the VSMC jak2 null mice exhibited significantly less Ang II-induced VSMC proliferation and migration in vitro and in vivo and more apoptosis. These results suggest that Jak2 plays a central role in the causation of Ang II-induced neointima formation following vascular injury and may provide a novel target for the prevention of neointima formation. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1026 / 1034
页数:9
相关论文
共 44 条
[1]   ANGIOTENSIN-II-STIMULATED PROTEIN-SYNTHESIS IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS [J].
BERK, BC ;
VEKSHTEIN, V ;
GORDON, HM ;
TSUDA, T .
HYPERTENSION, 1989, 13 (04) :305-314
[2]   Transcription-dependent silencing of inducible convergent transgenes in transgenic mice [J].
Calero-Nieto, Fernando J. ;
Bert, Andrew G. ;
Cockerill, Peter N. .
EPIGENETICS & CHROMATIN, 2010, 3
[3]   Potential role of JAK2 in cerebral vasospasm after experimental subarachnoid hemorrhage [J].
Chen, Gang ;
Wu, Jiang ;
Sun, Caixia ;
Qi, Meng ;
Hang, Chunhua ;
Gong, Yi ;
Han, Xiaodong ;
Shi, Jixin .
BRAIN RESEARCH, 2008, 1214 :136-144
[4]   ANGIOTENSIN-II INDUCES SMOOTH-MUSCLE CELL-PROLIFERATION IN THE NORMAL AND INJURED RAT ARTERIAL-WALL [J].
DAEMEN, MJAP ;
LOMBARDI, DM ;
BOSMAN, FT ;
SCHWARTZ, SM .
CIRCULATION RESEARCH, 1991, 68 (02) :450-456
[5]   Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice [J].
Daugherty, A ;
Manning, MW ;
Cassis, LA .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) :1605-1612
[6]   The role of inflammation in vascular injury and repair [J].
Davis, C ;
Fischer, J ;
Ley, K ;
Sarembock, IJ .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (08) :1699-1709
[7]   Oncogenic mechanisms in myeloproliferative disorders [J].
Delhommeau, F. ;
Pisani, D. F. ;
James, C. ;
Casadevall, N. ;
Constantinescu, S. ;
Vainchenker, W. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (24) :2939-2953
[8]   RAPID COLORIMETRIC ASSAY FOR CELL-GROWTH AND SURVIVAL - MODIFICATIONS TO THE TETRAZOLIUM DYE PROCEDURE GIVING IMPROVED SENSITIVITY AND RELIABILITY [J].
DENIZOT, F ;
LANG, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 89 (02) :271-277
[9]   ANGIOTENSIN-II INDUCES HYPERTROPHY, NOT HYPERPLASIA, OF CULTURED RAT AORTIC SMOOTH-MUSCLE CELLS [J].
GEISTERFER, AAT ;
PEACH, MJ ;
OWENS, GK .
CIRCULATION RESEARCH, 1988, 62 (04) :749-756
[10]   JANUS under stress - Role of JAK/STAT signaling pathway in vascular diseases [J].
Grote, K ;
Luchtefeld, M ;
Schieffer, B .
VASCULAR PHARMACOLOGY, 2005, 43 (05) :357-363